April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Inhibition Of Rho-kinase Counteracts The Proliferation, Motility, Contraction, And Dedifferentiation Of Retinal Pigment Epithelial Cells (RPEs)
Author Affiliations & Notes
  • Aysegul Tura
    Department of Ophthalmology, University of Luebeck, Luebeck, Germany
  • Farid Abdel Aal
    Department of Ophthalmology, University of Luebeck, Luebeck, Germany
  • Martin Rudolf
    Department of Ophthalmology, University of Luebeck, Luebeck, Germany
  • Sigrid Henke-Fahle
    University Eye Hospital, Center of Ophthalmology at the Eberhard-Karls University, Tuebingen, Germany
  • Salvatore Grisanti
    Department of Ophthalmology, University of Luebeck, Luebeck, Germany
  • Matthias Lueke
    Department of Ophthalmology, University of Luebeck, Luebeck, Germany
  • Footnotes
    Commercial Relationships  Aysegul Tura, None; Farid Abdel Aal, None; Martin Rudolf, None; Sigrid Henke-Fahle, None; Salvatore Grisanti, None; Matthias Lueke, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 937. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Aysegul Tura, Farid Abdel Aal, Martin Rudolf, Sigrid Henke-Fahle, Salvatore Grisanti, Matthias Lueke; Inhibition Of Rho-kinase Counteracts The Proliferation, Motility, Contraction, And Dedifferentiation Of Retinal Pigment Epithelial Cells (RPEs). Invest. Ophthalmol. Vis. Sci. 2011;52(14):937.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To examine the outcomes of Rho-kinase inhibition on the proliferation, migration, and contractility of the RPEs as well as the integrity of the cell-cell junctions and the extent of differentiation.

Methods: : Confluent primary bovine RPEs were maintained in low serum medium (2% v/v) for at least 8 weeks to induce differentiation whereas a subset of the cells were subcultured further until passage 5. The specific pharmacological inhibitor H-1152 was applied at the concentrations of 0.1-10 µM to inhibit the Rho-kinase activity. Cell proliferation was determined by the MTT test and Ki-67 immunostaining. Live-Dead and phalloidin stainings were performed to detect the cell viability and the organization of the actin cytoskeleton, respectively. The expression and localization of beta-Catenin, vimentin, and fibronectin were analyzed by immunocytochemistry and Western blot. The wound healing assay was performed on differentiated RPEs to test the effects of H-1152 on serum-induced migration. To examine the contractility, the RPEs were seeded onto the nerve fiber layer of porcine retinal explants and cultured with TGF-beta 2 and/or H-1152. The contraction of the underlying retina and the deposition of fibronectin were assessed by immunohistochemistry on the frozen sections and retinal mounts.

Results: : H-1152 exerted a significant anti-proliferative activity (p<0.05) in response to serum and PDGF-CC with no loss of viability. The RPEs incubated with TGF-beta 2 or 10% serum exhibited a dedifferentiated morphology with prominent levels of stress fibers, vimentin, and fibronectin as well as weakly formed cell-cell junctions with an increase in cytoplasmic and nuclear beta-catenin. However, in the presence of H-1152, the majority of the cells acquired a more differentiated phenotype characterized by the circumferential actin filaments, a reduction in the levels of vimentin and fibronectin, and the localization of beta-catenin mainly to the cell-cell junctions. H-1152 also reduced the extent of migration and retinal contraction together with a decrease in fibronectin deposition.

Conclusions: : Inhibition of Rho-kinase arises as a novel alternative for the treatment of the ocular complications marked by the dedifferentiation and enhanced fibrotic activity of the RPEs.

Keywords: retinal pigment epithelium • differentiation • proliferative vitreoretinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×